NCT06927817 - The Effect of Hyoscine-n-butylbromide on Nausea and Pain in Laparoscopic Cholecystectomy | Biotech Hunter

Enrollment

134

Participants

Timeline

Start Date

November 15, 2020

Primary Completion Date

November 15, 2021

Study Completion Date

April 8, 2025

Conditions

CholecystitisPainNausea

Interventions

DRUG

hyoscine-n-butylbromide, ondansetron

In patients in Group Hyoscine 20mg hyoscine-n-butylbromide in 100ml saline and in Group Ondansetron 4mg ondansetron infusion in 100ml saline will be administered in Group-O. The patients will be followed-up in terms of nausea, vomiting, and pain at the postoperative 15th, and 30th minutes and at the 3rd, 6th, 12th, and 24th hours.

DRUG

• hyoscine-n-butylbromide • ondansetron

In patients in Group Hyoscine 20mg hyoscine-n-butylbromide in 100ml saline and in Group Ondansetron 4mg ondansetron infusion in 100ml saline will be administered in Group-O. The patients will be followed-up in terms of nausea, vomiting, and pain at the postoperative 15th, and 30th minutes and at the 3rd, 6th, 12th, and 24th hours.

Trial Locations (1)

34668

University of Health Sciences Fatih Sultan Mehmet Health Research and Application Center,, Istanbul